These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 8597088)
41. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Bayever E; Iversen PL; Bishop MR; Sharp JG; Tewary HK; Arneson MA; Pirruccello SJ; Ruddon RW; Kessinger A; Zon G Antisense Res Dev; 1993; 3(4):383-90. PubMed ID: 8155979 [TBL] [Abstract][Full Text] [Related]
42. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Crooke RM Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572 [TBL] [Abstract][Full Text] [Related]
43. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Henry SP; Taylor J; Midgley L; Levin AA; Kornbrust DJ Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):473-81. PubMed ID: 9361906 [TBL] [Abstract][Full Text] [Related]
44. Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo. Carome MA; Kang YH; Bohen EM; Nicholson DE; Carr FE; Kiandoli LC; Brummel SE; Yuan CM Nephron; 1997; 75(1):82-7. PubMed ID: 9031275 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Grindel JM; Musick TJ; Jiang Z; Roskey A; Agrawal S Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):43-52. PubMed ID: 9512095 [TBL] [Abstract][Full Text] [Related]
47. [The toxic effects of high-dose Bcl-2 antisense phosphorothioate oligodeoxynucleotides incubation on cell line]. Lin Y; Lü L; Chen Z Zhonghua Yi Xue Za Zhi; 2000 Sep; 80(9):694-7. PubMed ID: 11798838 [TBL] [Abstract][Full Text] [Related]
48. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Alahari SK; Dean NM; Fisher MH; Delong R; Manoharan M; Tivel KL; Juliano RL Mol Pharmacol; 1996 Oct; 50(4):808-19. PubMed ID: 8863825 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Henry SP; Bolte H; Auletta C; Kornbrust DJ Toxicology; 1997 Jun; 120(2):145-55. PubMed ID: 9184201 [TBL] [Abstract][Full Text] [Related]
50. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854 [No Abstract] [Full Text] [Related]
51. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. Bishop MR; Iversen PL; Bayever E; Sharp JG; Greiner TC; Copple BL; Ruddon R; Zon G; Spinolo J; Arneson M; Armitage JO; Kessinger A J Clin Oncol; 1996 Apr; 14(4):1320-6. PubMed ID: 8648390 [TBL] [Abstract][Full Text] [Related]
52. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. Gomes dos Santos AL; Bochot A; Doyle A; Tsapis N; Siepmann J; Siepmann F; Schmaler J; Besnard M; Behar-Cohen F; Fattal E J Control Release; 2006 May; 112(3):369-81. PubMed ID: 16644054 [TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of antisense analogues in the central nervous system. Szklarczyk A; Kaczmarek L Neurochem Int; 1997 Sep; 31(3):413-23. PubMed ID: 9246683 [TBL] [Abstract][Full Text] [Related]
55. Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation. Uhlmann E; Ryte A; Peyman A Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):345-50. PubMed ID: 9303186 [TBL] [Abstract][Full Text] [Related]
56. Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides. Dheur S; Dias N; van Aerschot A; Herdewijn P; Bettinger T; Rémy JS; Hélène C; Saison-Behmoaras ET Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):515-25. PubMed ID: 10645777 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Agrawal S; Temsamani J; Tang JY Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7595-9. PubMed ID: 1881900 [TBL] [Abstract][Full Text] [Related]
58. Synthetic oligonucleotides: the development of antisense therapeutics. Monteith DK; Levin AA Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666 [TBL] [Abstract][Full Text] [Related]
59. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Peng B; Andrews J; Nestorov I; Brennan B; Nicklin P; Rowland M Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):15-27. PubMed ID: 11258618 [TBL] [Abstract][Full Text] [Related]
60. Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity. Zon G Toxicol Lett; 1995 Dec; 82-83():419-24. PubMed ID: 8597087 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]